As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction as a safer, more flexible alternative to traditional viral vectors. Touchlight’s groundbreaking synthetic dbDNA™ technology is at the forefront of this revolution, offering enhanced scalability, flexibility, and a superior safety profile compared to plasmid DNA (pDNA). This innovation opens up new therapeutic possibilities and paves the way for the next generation of genetic medicines.

In this article, Lisa Caproni, Ph.D., Associate Director of Applications, discusses how recent advancements in lipid nanoparticle (LNP) and electroporation technologies are unlocking the potential of nonviral gene therapies. Discover how dbDNA™ can overcome the limitations of viral vectors, allowing for re-dosable, scalable, and safer therapeutic solutions.

What You’ll Learn:

• The challenges of viral-vector-based therapies and how dbDNA™ provides a compelling alternative
• Innovations in nonviral gene delivery, including the latest breakthroughs in LNP and electroporation technologies
• Why dbDNA™ is poised to revolutionize genetic medicine with its superior scalability, safety, and efficacy